Fidelity Investments’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $121K | Hold |
90,300
| – | – | ﹤0.01% | 3719 |
|
|
2025
Q4 | $144K | Sell |
90,300
-108,300
| -55% | -$223K | ﹤0.01% | 3580 |
|
|
2025
Q3 | $508K | Buy |
+198,600
| New | +$626K | ﹤0.01% | 3026 |
|
|
2025
Q2 | – | Sell |
-11
| Closed | -$22 | – | 5346 |
|
|
2025
Q1 | $22 | Buy |
+11
| New | +$41 | ﹤0.01% | 5217 |
|
|
2024
Q3 | – | Sell |
-137,823
| Closed | -$2.82M | – | 5510 |
|
|
2024
Q2 | $2.82M | Sell |
137,823
-18,059
| -12% | -$605K | ﹤0.01% | 2259 |
|
|
2024
Q1 | $7.03M | Sell |
155,882
-1,528
| -1% | -$72.9K | ﹤0.01% | 1981 |
|
|
2023
Q4 | $7.43M | Sell |
157,410
-11,385
| -7% | -$633K | ﹤0.01% | 1949 |
|
|
2023
Q3 | $6.83M | Sell |
168,795
-104,545
| -38% | -$10.6M | ﹤0.01% | 1949 |
|
|
2023
Q2 | $29.1M | Buy |
273,340
+6,047
| +2% | +$2.01M | ﹤0.01% | 1480 |
|
|
2023
Q1 | $79.8M | Buy |
267,293
+4,578
| +2% | +$1.95M | 0.01% | 1070 |
|
|
2022
Q4 | $90.3M | Buy |
262,715
+363
| +0.1% | +$87.8K | 0.01% | 1010 |
|
|
2022
Q3 | $49.6M | Buy |
262,352
+17
| +0% | +$3.95K | 0.01% | 1246 |
|
|
2022
Q2 | $55.4M | Buy |
262,335
+2
| +0% | +$421 | 0.01% | 1213 |
|
|
2022
Q1 | $87.8M | Buy |
262,333
+17
| +0% | +$4.93K | 0.01% | 1126 |
|
|
2021
Q4 | $85.3M | Buy |
262,316
+25,729
| +11% | +$11M | 0.01% | 1181 |
|
|
2021
Q3 | $115M | Buy |
236,587
+41,911
| +22% | +$18.4M | 0.01% | 1041 |
|
|
2021
Q2 | $90.5M | Buy |
194,676
+55,311
| +40% | +$30.2M | 0.01% | 1161 |
|
|
2021
Q1 | $96.2M | Buy |
139,365
+14,241
| +11% | +$11.5M | 0.01% | 1078 |
|
|
2020
Q4 | $92.5M | Buy |
125,124
+4,710
| +4% | +$3.67M | 0.01% | 1067 |
|
|
2020
Q3 | $83.5M | Buy |
120,414
+109,958
| +1,052% | +$82.6M | 0.01% | 1001 |
|
|
2020
Q2 | $8.87M | Sell |
10,456
-27,387
| -72% | -$17.9M | ﹤0.01% | 1860 |
|
|
2020
Q1 | $13.5M | Sell |
37,843
-19,069
| -34% | -$6.85M | ﹤0.01% | 1581 |
|
|
2019
Q4 | $13.3M | Hold |
56,912
| – | – | ﹤0.01% | 1742 |
|
|
2019
Q3 | $6.41M | Buy |
56,912
+12,738
| +29% | +$2.01M | ﹤0.01% | 1974 |
|
|
2019
Q2 | $7.75M | Sell |
44,174
-8,404
| -16% | -$1.42M | ﹤0.01% | 1969 |
|
|
2019
Q1 | $8.32M | Sell |
52,578
-1,243
| -2% | -$153K | ﹤0.01% | 1923 |
|
|
2018
Q4 | $3.32M | Sell |
53,821
-28,575
| -35% | -$2.41M | ﹤0.01% | 2160 |
|
|
2018
Q3 | $10.1M | Sell |
82,396
-21,771
| -21% | -$3.23M | ﹤0.01% | 1930 |
|
|
2018
Q2 | $15.3M | Hold |
104,167
| – | – | ﹤0.01% | 1811 |
|
|
2018
Q1 | $17.1M | Buy |
+104,167
| New | +$17.4M | ﹤0.01% | 1785 |
|
Other funds holding BTAI
AC
OCM
VCM
VFT
Fidelity Investments's BTAI Position: Q1 2026 in Review
Fidelity Investments held its BioXcel Therapeutics (BTAI) position steady in Q1 2026 at 90,300 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #3719.
Fidelity Investments first reported a position in BTAI in Q1 2018 and has held it in 30 quarters since. The position peaked at $115M in Q3 2021. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.
- Fidelity Investments held 90,300 shares of BioXcel Therapeutics worth $121K as of Q1 2026.
- Fidelity Investments left its BioXcel Therapeutics share count unchanged in Q1 2026.
- BioXcel Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3719 holding.
- Fidelity Investments first reported a position in BioXcel Therapeutics in Q1 2018 and has held it in 30 quarters since.
- Fidelity Investments's BioXcel Therapeutics position peaked at $115M in Q3 2021.
- 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.